In the complex architecture of the United States tax code, the treatment of research and development (R&D) expenditures acts as a silent but powerful architect of corporate behavior. It dictates not just where American firms innovate, but whether they choose to invest in breakthrough technologies at all. As the global economy becomes increasingly digitized and interconnected, the divergence between domestic and foreign R&D tax treatment has emerged as a critical friction point, threatening to undermine the very competitiveness it was ostensibly designed to protect.
The Mechanics of R&D Taxation: Expensing vs. Amortization
At the heart of the debate lies the distinction between immediate expensing and long-term amortization. Under Section 174A of the tax code, domestic taxpayers are granted a choice: they may immediately deduct the full cost of domestic R&D or opt to amortize those costs over a period of at least 60 months. While immediate expensing is generally the preferred choice to maximize the time value of money, amortization serves as a useful tool for companies with net operating losses, allowing them to smooth deductions into future, more profitable years.
Conversely, foreign R&D is subject to a more rigid regime. Under Section 174, foreign-based research must be capitalized and amortized over a 15-year period. There is no option for immediate expensing. This disparity is not merely an accounting inconvenience; it creates a structural tax bias that penalizes U.S. companies for expanding their research footprint beyond American borders.
A Recent Chronology of Tax Policy
The current landscape is a product of rapid legislative shifts. In the early 2020s, the U.S. moved toward a requirement that all R&D—both domestic and foreign—be amortized. This shift was widely criticized by policy analysts and industry groups, including the Tax Foundation, for creating a significant tax hurdle for innovation.
Following this period of tightening, the One Big Beautiful Bill Act (OBBBA) reversed course, restoring the ability to expense domestic R&D immediately. However, the legislation pointedly excluded foreign R&D from this relief. The motivations behind this bifurcation were twofold: first, to reduce the overall budgetary cost of the tax relief measure, and second, to signal a policy preference for "onshoring" innovation. Yet, as the long-term impacts become clear, many analysts argue that this attempt to force domestic investment may be creating an economic "own goal."
The Hall-Jorgenson Framework: Why Timing Matters
To understand why the distinction between expensing and amortization is so critical, one must look to the foundational work of economists Robert Hall and Dale Jorgenson. In their seminal 1967 research, they demonstrated that the timing of tax deductions dictates the "user cost of capital"—the hurdle rate a project must clear to be considered financially viable.
Marginal Investment and the Hurdle Rate
When a firm evaluates a potential research project, it calculates the net present value of expected returns against the cost of capital. In a regime of full expensing, the present value of tax deductions (the variable z) equals 1. In this scenario, the tax burden on a marginal investment—an investment right on the cusp of profitability—effectively collapses to zero. The government, in effect, covers a portion of the upfront cost, which perfectly offsets the future tax liability generated by that investment’s returns.
Amortization disrupts this equilibrium. By forcing a firm to spread deductions over 15 years, the value of z drops significantly below 1. This pushes the user cost of capital upward, raising the hurdle rate for innovation. Consequently, projects that would have been profitable and socially beneficial under a neutral tax regime are abandoned, not because they lack technical merit, but because they are rendered unviable by the tax code.
The Myth of Substitution: Complementarity in Global R&D
A common rationale among proponents of the current bifurcated system is that by taxing foreign R&D more heavily, the U.S. can "force" companies to move those research activities back to American soil. However, economic data suggests this view is fundamentally flawed. International R&D is rarely a substitute for domestic research; rather, it is a complement.
Market Adaptation and Global Integration
Large multinational corporations utilize foreign R&D centers primarily for market adaptation. To export a product successfully, it must often be modified to comply with local regulations, suit regional infrastructure, or integrate with foreign payment and telecommunications systems. For instance, a pharmaceutical company may conduct clinical trials abroad to meet the regulatory requirements of foreign health ministries, or a software firm may tailor its interface for different languages and regional hardware standards.
By hindering these activities, the U.S. tax code does not necessarily move jobs to the U.S.; instead, it hampers the ability of U.S. firms to serve global markets. If a U.S. company cannot affordably adapt its products for foreign consumers, it simply loses market share to foreign competitors who are not saddled with similar tax burdens.
Evidence from Economic Institutions
Research from institutions like the Peterson Institute for International Economics (PIIE) supports the theory of complementarity. Economists such as Gary Hufbauer, Theodore Moran, and Lindsay Oldenski have consistently found that foreign R&D expenditures often create "interdependent competencies." Their work suggests that restricting the globalization of R&D by U.S. multinationals effectively stifles the parent company’s ability to innovate at home.
The Information Technology and Innovation Foundation (ITIF) has echoed these findings, noting that offshore research accelerates the adoption of new technologies and expands the firm’s broader knowledge network. Penalizing this activity is, therefore, a strategy that reduces a firm’s total cross-border knowledge production, providing no net gain for the domestic economy.
Implications for Global Competitiveness and M&A
Beyond the internal R&D operations of a firm, the current tax regime significantly alters the landscape for Mergers and Acquisitions (M&A).
In the modern innovation economy, acquiring a research-heavy startup is often a faster and more efficient way to innovate than building from scratch. However, if a U.S. firm attempts to acquire an R&D-heavy foreign target, it faces a structural disadvantage. A foreign competitor bidding for the same target can often expense the acquired R&D costs more favorably. For the U.S. firm, the 15-year amortization rule lowers the after-tax valuation of the target, making them less competitive in global bidding wars.
The Semiconductor Industry Association has warned that this disparity puts U.S. firms at a disadvantage when competing for innovative assets, particularly in sectors where M&A is a primary driver of growth, such as pharmaceuticals and high-tech manufacturing. The consequence is twofold:
- Lost Opportunity: U.S. firms lose out on acquiring key intellectual property, which weakens their long-term growth potential.
- Tax Base Erosion: As U.S. companies lose these competitive advantages, they may eventually be incentivized to relocate their tax residence to more favorable jurisdictions, ultimately reducing the global reach and revenue-generating capacity of the U.S. tax regime.
Conclusion: A Call for Tax Neutrality
The current treatment of R&D creates a tax-induced distortion that penalizes U.S. firms for operating in a global market. While the intent to encourage domestic investment is understandable, the economic reality is that modern innovation is global, interconnected, and highly sensitive to the cost of capital.
To maintain a competitive edge, the United States should move toward a neutral tax treatment of R&D expenditures, regardless of where that research is performed. By eliminating the punitive 15-year amortization schedule for foreign R&D, policymakers would reduce the hurdle rate for investment, encourage more efficient global operations, and improve the ability of American firms to compete for the world’s most valuable intellectual assets.
Tax policy should not be an anchor on innovation; it should be a platform. By ensuring that R&D is treated consistently, the U.S. can foster a more dynamic environment where American companies are empowered to innovate, expand, and compete on the global stage.
